^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | prizloncabtagene autoleucel (JNJ-4496) (CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published date:
01/12/2022
Excerpt:
Cellular Biomedicine Group Inc...today announced that the Food and Drug Administration (FDA) granted C-CAR039, a novel autologous bi-specific CAR-T therapy targeting both CD19 and CD20 antigens, both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL).
